Posts tagged Clinical Studies
Research Found an Association Between Muscle Health and NAD+ Abundance in Humans

Aging results in a gradual loss of skeletal muscle function over time. Sarcopenia, the progressive loss of skeletal muscle mass, strength, and performance with age, is one of the critical causes of functional decline in aged adults. Essential for supporting breathing, as well as moving and maintaining posture and balance, skeletal muscle makes up nearly 40% of a young, healthy individual’s total body mass and decreases between 3 to 8% each decade after 30 years of age.

Read More
Nicotinamide Riboside Supplementation Improves Ataxia Scores and Increases Antibody Levels in Ataxia Telangiectasia Patients

Ataxia telangiectasia (AT) is a rare, inherited neurodegenerative disorder characterized by cerebellar degeneration, immunodeficiency, and cancer predisposition. Previous preclinical research has shown that increasing NAD+ through nicotinamide riboside (NR), a vitamin B3 form, improved neurodegeneration and neuromuscular function in mouse models of AT. These results indicate that NAD+ boosting may be a potential therapeutic strategy for AT. Researchers of this study set out to investigate the effects of boosting NAD with NR in AT patients.

Read More
Combined Metabolic Activators Therapy Reduces Liver Fat by 10% In Nonalcoholic Fatty Liver Disease Patients

A recent phase 2 clinical trial published on Cell Press Sneak Peek, a preprint publication website for papers under review by Cell Press Journals, found that a novel combined metabolic cofactor supplement (CMCS) cocktail which included nicotinamide riboside (NR) significantly reduced hepatic fat in nonalcoholic fatty liver disease (NAFLD) patients by 10%.

Read More
Combined Metabolic Activators (CMAs) Improve Cognitive Functions without Altering Motor Scores in Parkinson's Disease

A new study assessing whether administration of a mixture of Combined Metabolic Activators (CMAs), including NAD+ precursor nicotinamide riboside (NR), could treat Parkinson’s disease patients, is now available on the open access preprint publication server medRxiv.org.

Parkinson’s Disease (PD) is a neurodegenerative disease largely characterized by impairments in motor functions, including tremors, stiffness, slow movement, or difficulty in maintaining balance, as well as in non-motor functions, such as cognitive impairment [1]. Those who suffer from PD may also experience mental and behavioral changes, memory difficulties, and depression.

Read More
Combined Metabolic Activators (CMAs) Improves Cognitive Functions in Alzheimer’s Disease

Results of a new phase 2 clinical study assessing whether administration of a mixture of Combined Metabolic Activators (CMAs) including NAD+ precursor nicotinamide riboside (NR) could treat Alzheimer’s Disease patients, are now available on the open access preprint publication server medRxiv.org.

Alzheimer’s Disease (AD), a neurodegenerative disease characterized by impaired memory and cognitive decline, affects more than 44 million people worldwide [1, 2]. The disease not only causes tremendous human suffering, but also puts an enormous strain on the healthcare system, families, and federal budget.

Read More
Phase 3 Clinical Trial Demonstrates Combined Metabolic Activators (CMAs) Accelerates Recovery in Mild-to-Moderate COVID-19

Results of a phase 3, double-blind, placebo-controlled trial assessing whether a mixture of Combined Metabolic Activators (CMAs) targeted at mitochondrial function, could improve metabolic function and aid the recovery of mild-to-moderate COVID-19 infected individuals, are now available in the peer-reviewed journal Advanced Science.

The study, conducted at Umraniye Teaching and Research Hospital, University of Health Sciences, Istanbul, Turkey, found that the CMAs, which included nicotinamide riboside (NR), L-serine, N-acetyl-L-cysteine (NAC), and L-carnitine tartrate, when delivered in combination with standard of care, experienced a statistically significant, 3.5 day reduction in recovery time in the COVID-19 infected patients.[1]

Read More
New Phase 2 Clinical in COVID-19 Patients Finds Hydroxychloroquine (HCQ) Plus Nutritional Protocol Including Nicotinamide Riboside Significantly Improved Recovery Time Vs. HCQ Alone

On the heels of two previously published preclinical studies investigating the effect of viral infection on NAD+ levels, new clinical research in 93 mild-to-moderate COVID-19 infected patients is now available on the open access preprint publication server medRxiv.org.

Read More
NAD+ Liver Depletion is Linked to Alcohol-Related Liver Disease in Humans

A new study recently published in Hepatology Communications  and conducted by investigators from The University of Birmingham, its affiliated hospital, and the University of Iowa, found that NAD+ levels were significantly reduced in liver samples obtained from those undergoing transplant surgery for alcohol-related liver disease (ARLD), suggesting that NAD+ may play a critical role in mitigating liver damage.

Read More